Kyowa Kirin Takes Back Rocatinlimab as Amgen Exits Collaboration
Event summary
- Kyowa Kirin regains full control of rocatinlimab development after terminating collaboration with Amgen.
- Regulatory submission for rocatinlimab in moderate-to-severe atopic dermatitis planned for H1 2026.
- Phase 3 ROCKET program includes 8 pivotal studies with over 3,300 patients enrolled.
- Rocatinlimab targets OX40 receptor, offering potential as first T-cell rebalancing therapy for atopic dermatitis.
- Amgen will continue manufacturing rocatinlimab despite ending development partnership.
The big picture
Kyowa Kirin's decision to regain control of rocatinlimab reflects a strategic bet on the drug's potential to address significant unmet needs in atopic dermatitis, a market with growing demand for long-term disease control solutions. The move comes as Amgen prioritizes its portfolio, highlighting the shifting dynamics in biopharmaceutical collaborations where companies often reassess partnerships based on evolving strategic priorities. With positive Phase 3 data in hand, Kyowa Kirin now faces the challenge of translating clinical success into commercial viability in a competitive therapeutic landscape.
What we're watching
- Regulatory Momentum
- Whether Kyowa Kirin can successfully navigate the regulatory submission process and secure approval for rocatinlimab in the U.S. and Japan.
- Commercial Strategy
- How Kyowa Kirin plans to position rocatinlimab in the competitive atopic dermatitis market, particularly against existing biologics and JAK inhibitors.
- Clinical Expansion
- The pace at which Kyowa Kirin will expand rocatinlimab's clinical indications beyond atopic dermatitis into other inflammatory conditions.
Our editorial coverage: